PeptiDream

Japan-based biopharmaceutical company (TSE: 4587) founded in 2006, headquartered in Kawasaki. Specializes in cyclic and macrocyclic peptide drug discovery using proprietary PDPS platform. Has generated dozens of clinical candidates across multiple pharma partners. Key player in the growing cyclic peptide therapeutics space with projected 21.4% CAGR through 2030.

PeptiDream is listed as a institutional supplier in the peptide supply chain, serving Asia markets from Japan (Kawasaki). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. Verification is supported by 1 independent source, including documentation review and cross-referencing against public records. This supplier has a strong confidence score, indicating a high level of verification and reliability for B2B sourcing.